Date: 2013-03-20
Type of information: Commercialisation agreement
Compound: Veregen® ointment (made from the extract of green tea leaves - catechins)
Company: MediGene (Germany) SynCore Biotechnology (Taiwan)
Therapeutic area: Infectious diseases - Gynecology - Women's health
Type agreement: commercialisation
Action mechanism:
Disease: External genital warts
Details: * On May 18, 2011, MediGene AG has signed an exclusive license and supply agreement with SynCore Biotechnology, a subsidiary of the Sinphar Group, for the commercialization and marketing of Veregen® ointment in Taiwan for the treatment of genital warts. MediGene will supply Sinphar with API, Sinphar will produce the drug in its Taiwan manufacturing facilities and SynCore Bio will market and sell the ointment in Taiwan.
MediGene has already entered into several marketing partnerships for Veregen®, e.g. with Nycomed, Inc. for the USA, with Abbott for Germany, Austria, and Switzerland, with Laboratoires Expanscience for France, and with a number of other partners across Europe, America, and Asia. MediGene is planning to continue this global licensing strategy.
Veregen® is currently available on the US, German, and Austrian markets. A second wave of marketing applications within the European mutual recognition procedure is planned, with Germany serving as the reference state in this process.
Financial terms: Financial details of the agreement were not disclosed.
Latest news: * On March 20, 2013, Medigene and SynCore Biotechnology have expanded the existing exclusive licensing and supply contract into new regions for the supply and marketing of the Veregen® ointment for the treatment of genital warts. Along with existing agreements in Taiwan, SynCore will now be responsible for the approval process and commercialization of the drug for the treatment of genital warts throughout Asia* Afghanistan, Bangladesh, Bhutan, Brunei, Burma, Cambodia, Indonesia, Iran, Iraq, Japan, Laos, Maldives, Mongolia, Nepal, Pakistan, Philippines, Singapore, Sri Lanka, Thailand and Vietnam and excl. China and Korea), in Australia and New Zealand. In addition to income from the production and supply of the ointment and the active ingredient, Medigene will receive payment when specific milestones are reached. Medigene already has partnerships in Asia for the distribution of Veregen® in China (GC Rise Pharmaceutials) and South Korea (Kolon Pharmaceuticals).
